VOYXACT

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Efficacy and SafetyIga NephropathyNephropathyPrimary Membranous Nephropathy

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

1

Dacogen

Sun Pharmaceutical Industries, Inc.

Phase 3

32

Taxotere

AAvyxa

Phase 3

43

Alka-Seltzer

AAbbott

Phase 3

14

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

15

VOYXACT

Otsuka

Phase 3

16

Mitomycin C

GGynecologic Oncology Group

Phase 3

27

Apatinib Mesylate

BBukwang Pharmaceutical

Phase 3

18

Hemay005

GGanzhou Hemay Pharmaceutical Co., Ltd

Phase 3

29

IN-B00009

HHK inno.N Corporation

Phase 3

110

IBI302

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

IgA Nephropathy2 trials

A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies Adults With Immunoglobulin A Nephropathy

Active, not recruiting·Otsuka·Phase 2·NCT06740526·56 enrolled

A Phase 3, Open-label, Single-arm, Repeat-dose Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Sibeprenlimab Administered Subcutaneously in Children and Adolescents With Immunoglobulin A Nephropathy

Not yet recruiting·Otsuka·Phase 3·NCT07770815·24 enrolled

Immunoglobulin A Nephropathy2 trials

A Phase 3b, Open-label, Single-arm, Patient Experience Study of Povetacicept Injection (Via Autoinjector) as Compared to Sibeprenlimab Injection (Via Prefilled Syringe) in Adults With Immunoglobulin A Nephropathy

Not yet recruiting·Vertex Pharmaceuticals·Phase 3·NCT07890909·40 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.

Active, not recruiting·Otsuka·Phase 3·NCT05248646·530 enrolled

Efficacy and Safety1 trial

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

Active, not recruiting·Otsuka·Phase 2·NCT06928142·83 enrolled

Nephropathy1 trial

Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

Enrolling by invitation·Otsuka·Phase 2/3·NCT05248659·600 enrolled

Primary Membranous Nephropathy1 trial

A Phase 2, Multicenter, Open-label Trial to Evaluate the Efficacy and Safety of Sibeprenlimab in Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease

Not yet recruiting·Otsuka·Phase 2·NCT07861113·20 enrolled

1 more indication

Unspecified1 trial

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Completed·Otsuka·Phase 1·NCT07105124·24 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News